Pelthos Therapeutics (PTHS) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Oppenheimer | Maintained | Outperform | $64.00 from $66.00 | Aug 14, 2026 |
| Oppenheimer | Maintained | Outperform | $66.00 from $62.00 | May 15, 2026 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $50.00 | Apr 1, 2026 |
| Oppenheimer | Maintained | Outperform | $62.00 from $60.00 | Mar 20, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $60.00 | Mar 19, 2026 |
| Piper Sandler | Initiated Coverage | Overweight | $48.00 | Feb 27, 2026 |
| Roth Capital | Maintained | Buy | $55.00 from $57.00 | Feb 26, 2026 |
| Oppenheimer | Maintained | Outperform | $60.00 from $57.00 | Jan 26, 2026 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $60.00 | Dec 3, 2025 |
| Lake Street | Initiated Coverage | Buy | $50.00 | Dec 3, 2025 |
| Roth Capital | Initiated Coverage | Buy | $57.00 | Nov 25, 2025 |
| Oppenheimer | Maintained | Outperform | $57.00 from $50.00 | Nov 14, 2025 |
| Oppenheimer | Initiated Coverage | Outperform | $50.00 | Sep 2, 2025 |
| Alliance Global Partners | Initiated Coverage | Buy | — | Jun 18, 2024 |
Frequently asked questions
Is PTHS a buy, sell, or hold?
Analysts covering Pelthos Therapeutics currently average a Buy rating: 7 buy, 0 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What is the latest analyst rating on PTHS?
On Aug 14, 2026, Oppenheimer maintained Pelthos Therapeutics at Outperform with a price target of $64.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.